Orion animal health sales up 5% in Q3
Orion Corporation’s third-quarter animal health sales rose by 4.8% to €16.4 million ($21.2 million), the Finnish company reports. At the nine-month stage, revenue was up by 6.7% at €49.1 million. The sedative products Dexdomitor (dexmedetomidine), Domitor (medetomidine), Domosedan (detomidine) and Antisedan (atipamezole) rose by 20% and accounted for a third of the animal health division’s revenue. Pfizer, Orion’s marketing partner for animal sedatives, launched Domosedan gel in the US at the end of July.